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REVIEW
The sweet branch of metabolic 




In the first science review on the then nascent Metabolic Engineering field in 1991, Dr. James E. Bailey described 
how improving erythropoietin (EPO) glycosylation can be achieved via metabolic engineering of Chinese hamster 
ovary (CHO) cells. In the intervening decades, metabolic engineering has brought sweet successes in glycoprotein 
engineering, including antibodies, vaccines, and other human therapeutics. Today, not only eukaryotes (CHO, plant, 
insect, yeast) are being used for manufacturing protein therapeutics with human-like glycosylation, newly elucidated 
bacterial glycosylation systems are enthusiastically embraced as potential breakthrough to revolutionize the biophar-
maceutical industry. Notwithstanding these excitement in glycoprotein, the sweet metabolic engineering reaches 
far beyond glycoproteins. Many different types of oligo- and poly-saccharides are synthesized with metabolically 
engineered cells. For example, several recombinant hyaluronan bioprocesses are now in commercial production, and 
the titer of 2′-fucosyllactose, the most abundant fucosylated trisaccharide in human milk, reaches over 20 g/L with 
engineered E. coli cells. These successes represent only the first low hanging fruits, which have been appreciated sci-
entifically, medically and fortunately, commercially as well. As one of the four building blocks of life, sugar molecules 
permeate almost all aspects of life. They are also unique in being intimately associated with all major types of biopoly-
mers (including DNA/RNA, proteins, lipids) meanwhile they stand alone as bioactive polysaccharides, or free soluble 
oligosaccharides. As such, all sugar moieties in biological components, small or big and free or bound, are important 
targets for metabolic engineering. Opportunities abound at the interface of glycosciences and metabolic engineer-
ing. Continued investment and successes in this branch of metabolic engineering will make vastly diverse sugar-con-
taining molecules (a.k.a. glycoconjugates) available for biomedical applications, sustainable technology development, 
and as invaluable tools for basic scientific research. This short review focuses on the most recent development in the 
field, with emphasis on the synthesis technology for glycoprotein, polysaccharide, and oligosaccharide.
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Background
Glycosylation is the most prevalent and most important 
co- and post-translational modifications of proteins and 
lipids. It is estimated that more than 50 % of human pro-
teins are glycosylated. Glycosylation of proteins impacts 
the processing, distribution, and metabolism as well as 
the biological functions of most proteins. Glycans on 
proteins and lipids serve as molecular recognition ele-
ments in vital biological processes such as cell growth, 
differentiation, development, cell–cell interactions, 
cell migrations, host-microbe interactions, and blood 
haemostasis [1]. Aberrant glycosylation often signi-
fies a biological transformation of medical significance. 
An example is a hexasaccharide shown in Fig.  1a, first 
described as human embryonic intestinal tissue marker 
and later defined as the SSEA-3 cancer antigen or more 
commonly known as Globo H antigen, is often associated 
with tumor aggressiveness [2]. Expression of a specific 
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α-2,6-sialyltransferase was implicated in metastasis from 
the breast to the brain by increasing cellular adhesion to 
brain tissue [3]. Altered glycosylation has also been impli-
cated in many different types of diseases and numerous 
pathological states such as neurodegenerative disorders, 
rheumatoid arthritis, and cystic fibrosis [4]. Besides pre-
sent as glycoproteins or glycolipids on cell surfaces, sol-
uble glycans or free oligosaccharides are also important 
constitutes that play very important roles in biological 
systems. For example, in human milk, soluble oligosac-
charides, with as many as 200 distinct structures, form 
the third most abundant component in human milk (after 
lactose and lipid). Increasing evidence suggests that they 
are anti-infective [5], prebiotic [6], with additional role in 
modulating immune functions [7]. Additionally, polysac-
charides are polymers of sugars, which are synthesized by 
organisms of all domains and exhibit diverse functions 
that find numerous in vivo and in vitro applications.
The widespread occurrence of glycosylation and its 
broad impact in biological processes underscores the 
importance of studying glycosylation. To study glycans 
and probe their roles in a biological system significant 
amount of pure molecules are needed. Besides basic 
research, there are a wide range of opportunities of uti-
lizing oligosaccharides, polysaccharides, and glycopro-
teins and other glycoconjugates for diagnosis, vaccine 
development, as new drug entities, and many other med-
ical applications. Unfortunately, these potential applica-
tions are all impeded by the lack of large scale synthesis 
technology for these molecules. In fact, these molecules 
are so scarce that it is challenging to gather just enough 
materials for research, let alone pre- and clinical tests. 
Take oligosaccharides as an example, very few molecules 
are available commercially, and for those available for 
purchase, a typical price is several hundred dollars per 
milligram, limiting their use to analytical standards. A 
recent report by National Academy Sciences concludes 
that glycoscience is critical for advancement of human 
health and for sustainability of the planet [8]. The report 
recognizes that the investment in research in this glyco-
science has lagged far behind from other aspects of life, 
especially nucleic acids and proteins [8, 9]. This statement 
is a true reflect of the current state of glycoscience. Now-
adays, a desired DNA sequence can be purchased with 
very low price (~$0.23 per base) and virtually any protein 
can be synthesized with recombinant DNA technology. 
Fig. 1 Globo H (a) and globo trisaccharide synthesis using in vitro method (b) with an α1,4 galactosyltransferase (α 1,4-GalT) and a UDP-Gal regen-
eration using four enzymes (PK, GalK, AtUSP, PPA) and PEP, ATP, UTP, Gal as starting material. This process leads to one glycosidic bond formation. 
Abbreviation used: Glc (glucose); Gal (galactose), GalNAc (N-acetylgalactosamine), Fuc (fucose); Lac (lactose). Other abbreviations are defined in text 
or as commonly used in literature (e.g. ATP). Figure 1 is adopted from Tsai et al. (2013) [2]
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Comparing to the ease of obtaining DNA and proteins, 
glycans of desired sequence (structure) is very difficult to 
obtain. Like nucleic acids, proteins and lipids, glycans are 
one of the four fundamental building blocks of life. The 
under-development of glycosciences, if not addressed, 
would ultimately impact our overall understanding of and 
advances in biological sciences and impede development 
of medical and other technological fields. Thus there is an 
urgency to accelerate the research in glycosciences. One 
critical element in glycoscience research is the availability 
of glycans or glycoconjugates. Therefore, bringing glycan 
synthesis technology on the par with those for proteins 
and DNA/RNA synthesis is urgently needed.
Metabolic engineering, since its inception in late 80s, 
has grown to be a field impactful in the synthesis of a 
variety of molecules of commercial and societal impor-
tance. Over the past decades, its use in the synthesis of 
sugar-containing molecules has gained significance, 
with oligosaccharides, polysaccharides, and glycopro-
teins particularly noteworthy. In this review, metabolic 
engineering challenges common to these glycosyltrans-
ferase-catalyzed molecules are analyzed and successful 
examples are showcased to emphasize the power of met-
abolic engineering as an enabling technology.
Oligosaccharides
Oligosaccharides are small soluble molecules that serve 
important roles in biological systems. To obtain sig-
nificant amount of pure oligosaccharides from natural 
sources is difficult. This is because they are often hetero-
geneous, present in minute amount, conjugated to pro-
teins and other biological materials. Chemical synthesis 
of complex carbohydrates is difficult due to similarity of 
hydroxyl groups within a sugar molecule and is further 
complicated by the stereochemistry (a.k.a. anormity) that 
generates structural isomers when linking two or more 
monosaccharides together in the synthesis of an oligo-
saccharide. To differentiate subtle differences between 
hydroxyl groups requires protection and de-protection 
groups that add to an already lengthy synthesis route, 
leading to low yield and often with numerous byproducts 
requiring complicated workup [10]. Isolating a desired 
isomer from structurally similar isomers requires addi-
tional steps or reagents, increasing complexity and cost 
of a synthesis process. Biological methods are not as 
straightforward as proteins since oligosaccharides are not 
direct gene products. The biogenesis of an oligosaccha-
ride often involves several pathways, further complicated 
by the regulations inherent in biological processes, such 
as feedback control and catabolite repression.
Numerous chemical and enzymatic methods were 
reported for synthesis of oligosaccharides as a mean to 
provide mg quantities of materials [11–14]. Chemo- and 
in  vitro enzymatic methods are particularly useful to 
derive non-natural oligosaccharides [15, 16]. The chemo- 
and enzymatic synthesis method can be illustrated with 
Globo H (Fig.  1a) as an example. The potential use of 
this hexasaccharide in anticancer vaccine has moti-
vated chemists to develop several useful synthesis tech-
nologies [2]. Most notable is the one-pot programmable 
method. However, it seems that executing the method 
still requires highly skilled experts and customized rea-
gents that are only available at limited numbers of elite 
laboratories. Enzymatic methods offer an alternative, 
which could be advantageous in reducing steps involved 
in the synthesis, and byproduct formation [17]. However, 
in vitro method utilizing isolated glycosyltransferases also 
present challenges due to the need for activated sugar 
precursors (or sugar nucleotides) as enzyme substrates. 
Sugar nucleotides are too expensive to be used in stoi-
chiometric ratio, thus elegant regeneration methods were 
developed (Fig. 1b). However, these methods still require 
significant input of expensive high energy compounds in 
the form of ATP (or GTP, UTP, CTP), phosphoenolpyru-
vate (PEP) and up to four enzymes in each sugar nucleo-
tide regeneration. In a recent gram-scale synthesis of a 
trisaccharide intermediate (Globo-trisaccharide, Fig. 1b), 
4.55 g PEP was used along with 28 mg ATP and 69 mg 
UTP, and four recombinant enzymes for the regenera-
tion of UTP-Gal (Fig. 1b). Note that this much material 
consumption is used to make only one single glycosidic 
bond, underscoring the difficulty involved in the process. 
Often biologically significant glycans are complex tetra-, 
penta- or hexa-saccharides. Thus, their synthesis requires 
several glycosidic bond formations. While the cost asso-
ciated with PEP and other high energy compounds may 
be tolerable for single glycosidic bond formation, further 
scale up to kg or larger scale, or more complex oligosac-
charides using this method would be difficult. Addition-
ally, regeneration of each sugar nucleotide (as shown in 
Fig. 1b) requires up to four recombinant enzymes, which 
means four separate fermentation processes for the 
enzyme production before an in vitro reaction could be 
set up. Thus, overall, while this method has served well 
for obtaining limited amount of pure oligosaccharides, 
further scaling up is problematic due to both cost and 
steps involved in the synthesis process.
To overcome the aforementioned problems with the 
in  vitro method, in  vivo methods such as using bacte-
rial cell coupling was developed in Japan for several sim-
ple oligosaccharides [18]. For example, the microbial 
coupling methods were successfully used to synthesize 
sialylated lactose to achieve 33  g/L product titer [19]. 
However, this method is still cumbersome as one single 
glycosidic bond requires up to four bacterial strains (four 
fermentation steps). Improvement over this coupling 
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method is the single-strain method developed by Semain 
et  al. [20, 21], in which all enzymes required for sugar 
nucleotide regeneration and glycosyltransferase enzymes 
were cloned into a single bacterium. This method has 
been shown to be successful to generate simple oligosac-
charides to titers similar to those obtained with microbial 
coupling. For example, 25 g/L product titer for 3′-sialyl-
lactose [22] and 34 g/L titer for 6′-sialyllactose [23] were 
obtained in a high cell density cultivation of engineered 
E. coli using glycerol as carbon and energy source. Poten-
tially, this method has several important advantages over 
the in  vitro enzymatic or microbial coupling methods. 
The metabolic engineered strains, once developed, could 
be used in a fermentation process in large bioreactors 
for kg or larger quantity synthesis. The in  vivo method 
is cost-effective as it does not require any expensive high 
energy compounds. The valuable oligosaccharides can 
be produced from inexpensive carbon sources. When E. 
coli is used, cheap medium and fast growth of biocatalyst 
ensures cost-effective synthesis. Additionally, the syn-
thesis is a single-fermentation process, which could be 
used to accomplish multiple glycosidic bond formation. 
Shown in Fig. 2 is an example of a galactosyltransferase 
enzyme catalyzed reaction with lactose as acceptor sugar 
and UDP-Gal as donor. At the very minimum, a glyco-
sidic bond formation requires a glycosyltransferase, one 
sugar acceptor and a donor substrate in the form of sugar 
nucleotide. Provision of these three essential components 
is no small feat [10, 24].
Glycosyltransferases (GTs)
Since the in  vivo one strain approach is dominated by 
bacteria, such as Agrobacterium sp. [25–27], Corynebac-
terium glutamicum [28], E. coli [e.g. 29–31], and Lac-
toccous casei [32], bacterial glycosyltransferases are 
primarily used as they are more likely to be expressed 
in these bacterial hosts. Several well-characterized bac-
terial glycosyltransferases were used in metabolic engi-
neering, including Helicobacter fucosyltransferases [33], 
Neisseria and Photobacterial sialyltransferases [22, 23], 
Neisseria galactosyltransferases [29], and Helicobacter 
GlcNActransferase [30]. While recent explosive advances 
in genomics have significantly increased the number of 
bacterial glycosyltransferases candidates, the increase 
in new glycosyltransferases used in metabolic engineer-
ing has been rather limited. This is because classification 
of GTs based on sequence similarity or other structure 
based analysis does not predict their acceptor specificity 
and the type of linkages [11, 34]. A definitive association 
of a potential GT gene with its functionality, the substrate 
specificity, the linkage type requires careful experimental 
characterizations, which are hampered by the lack of high 
throughput methods for enzyme assays, and both availa-
bility and cost of potential substrates and products. Even 
with bacterial GTs, an active expression in E. coli cannot 
be assumed a priori. One reason for this is that GTs are 
usually membrane proteins [35], its active expression and 
correct folding and insertion into the membrane may 
require certain factors (such as chaperones) that a host 
microbe does not have. Additionally, GTs from patho-
genic bacteria have certain peculiarity that impacts its 
heterologous expression. For example, some GTs, such as 
fucosyltransferases, appear to be dependent on disulfide 
bond formation for activity [36], and may require host 
engineering for functional expression in cytosol. Thus, 
their soluble expression often requires a fusion partner 
[17, 37], which increases the size of the recombinant pro-
tein and the burden on host cells.
Acceptor
The challenge of bringing an acceptor sugar into the 
cytosol lies in the fact that acceptor for the GTF is also a 
sugar. Additionally, a second sugar is needed as an energy 
source (Fig. 2). Further, a third sugar (such as fucose and 
sialic acid) may be needed in the synthesis of donor sub-
strate. A near universal metabolic regulation known as 
carbon catabolite repression (CCR) prevents cells from 
engaging more than one sugar at a time. To overcome this 
challenge, researchers developed some innovative strate-
gies such as producing acceptor in situ [38]. In addition, 
non-sugar energy source such as glycerol could be used. 
Furthermore, native monosaccharide and disaccharide 
transporter could be activated through mutation [21] or 
inducible overexpression [26]. However, the success of 
these strategies are highly acceptor specific, no generally 
applicable method is available to address the issue except 
passive diffusion, which requires providing an acceptor 
sugar at a very high concentration. Since acceptor sugars 
Fig. 2 Illustration of a glycosyltransferase catalyzed reaction taking 
place inside a bacterial cell. Besides an exogenous carbon source in 
the synthesis of sugar nucleotide, UDP-Gal, an exogenous energy 
source and its conversion to cellular energy (such as ATP, UTP, etc.) is 
required
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are typically not readily available, large excess of accep-
tors is generally not feasible in most cases.
Donor
Provision of donor substrate requires tapping into host 
metabolism for necessary energy needed for the synthe-
sis. To provide sufficient sugar nucleotide synthesis, one 
most commonly used method is selective overexpression 
of enzymes associated with sugar nucleotide synthesis 
[31, 32]. This may also include expression of heterolo-
gous enzymes and install a completely new pathway. For 
example, for GDP-fucose synthesis, besides using the de 
novo synthesis, the discovery of a unique bifunctional 
enzyme FKP from Bacteroids fragilis [39] that synthesize 
GDP-Fuc from fucose, ATP, GTP, provided research-
ers the salvage pathway for fucosylated oligosaccharides 
[33, 40]. Another method is to use hosts that have an 
outstanding capability for sugar nucleotide synthesis. 
Agrobacterium sp. ATCC31749 is a producer of a homo 
glucose polymer, curdlan. Under optimal conditions, it 
can accumulate more than 90 g/L curdlan. The strain was 
engineered to synthesize and regenerate UDP-Gal for 
production of a disaccharide, LacNAc [25] and a trisac-
charide containing α-gal epitope [26]. Multigrams of tar-
get oligosaccharides can be derived from 1 liter culture 
of engineered Agrobacterium cells without any input of 
expensive high energy compounds, demonstrating the 
effectiveness of this approach. Since polysaccharide syn-
thesis in microbes is common, the strategy of harnessing 
naturally existing mechanisms to recycle sugar nucleo-
tide for oligosaccharide synthesis could potentially be a 
more general approach.
In light of the challenges highlighted above, the suc-
cess of the in  vivo one-strain approach is particularly 
encouraging. The titers of two trisaccharides, 2′-fucosyl-
lactose and 3′-sialyllactose, from high cell density E. coli 
culture could reach 22 and 34 g/L, respectively [23, 33]. 
However, successful processes with impressive prod-
uct titers were only reported for relatively small oligo-
saccharides, mostly trisaccharides. Extending the same 
strategy for more complex oligosaccharides (containing 
four or more monosaccharides) resulted in precipitously 
lower titer, mostly less than 1 g/L [30, 41, 42]. This sug-
gests that the in vivo method cannot be simply extended 
to complex oligosaccharides. As target oligosaccharides 
become more complex, the number of glycosidic bond to 
be formed increases, along with escalated cellular energy 
demand, and increased number of sugars that a produc-
ing strain necessarily have to engage, and more complex 
of biochemical networks. A satisfactory engineering solu-
tion need to confront these challenges before the in vivo 
one strain approach can be used as a method of choice 
for complex oligosaccharide synthesis.
Polysaccharides
Polysaccharides are a class of polymers of diverse chemi-
cal structures, physical properties, and biological func-
tions. Over the past decades, numerous polysaccharides 
have been made into successful commercial products. 
Xanthan Gum, alginate, bacterial cellulose, curdlan, 
levan, and hyaluronic acid (a.k.a hyaluronan or HA) 
are just a few such examples [43]. These polysaccha-
ride products are used in a wide array of applications, 
including medical treatments, eye surgery, drug deliv-
ery, cosmetics, food processing and additives, petroleum 
recovery. While some of these polysaccharides already 
capture multi-billion dollar commercial values, they 
represent only a tip of an iceberg of nature’s bounty. In 
fact, polysaccharides are produced by organisms of all 
domains as intracellular, capsular, extracellular products, 
or as covalently linked components in a large matrix. 
Microbes and other organisms, however, are evolved to 
produce the types of polysaccharides with the amounts 
closely match their own needs. As such, often natural iso-
lates are not optimized to achieve productivity, titer, and 
yield dictated by a commercially viable bioprocess. Meta-
bolic engineering plays a vital role in strain development 
for polysaccharide synthesis. This is illustrated by the 
recent rapid rise of recombinant synthesis technologies 
for hyaluronan (HA), several of which have successfully 
moved into the commercial realm [44]. HA is a linear 
polymer of a repeating disaccharide, β1,3 D-N-acetyl-
glucosamin (GlcNAc) β1,4 glucuronic acid (GlcA). It 
finds application in numerous biomedical procedures 
such as ophthalmic surgery and osteoarthritis treatment 
[45]. Traditional methods of production involve extrac-
tion from animal tissues and fermentation of pathogenic 
Streptococcus, raising safety concerns. Today, metabolic 
engineering has made recombinant HA synthesis possi-
ble in several GRAS (generally regarded as safe) micro-
organisms, including Agrobacterium sp. [45], Bacillus 
subtilis [46] and Pichia pastoris [47], non-pathogenic E. 
coli strains [48, 49], Corynebacterium glutamicum [50], 
food grade strains, Lactococcus lactis [51, 52] and Stre-
tococcus thermophilus [53]. With process optimization, 
recombinant strains can approach product titer similar to 
the Streptococcus strain, 5–10 g/L [46, 48]. Much beyond 
10  g/L in titer is probably not attainable as the growth 
medium becomes very viscous, limiting oxygen and other 
necessary nutrient for the biosynthesis. Recent research 
has focused on increasing molecular weight of the poly-
mer from recombinant processes, as various applications 
of HA are highly dependent on the molecular weight of 
the polymer [54, 55]. While high molecular weight HA is 
prized for certain medical procedures, the low molecular 
weight polymer is valuable for cosmetic use. The mecha-
nism governing the molecular weight of HA polymer is 
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yet to be elucidated completely. However, evidence gath-
ered in several producing microbes suggest relative levels 
of two precursor molecules, UDP-GlcNAc and UDP-
GlcA, are one of the important determining factors [56]. 
Accordingly, the approach taken by Jia et al. by indepen-
dently controlling the levels of HA synthase and GlcA 
synthesis was effective in obtaining a high molecular 
weight HA (up to 5.4 MD) with low polydispersity [57].
HA is only one of glycosaminoglycans (GAGs) of 
medical importance. Heparin, another important GAG 
polysaccharide, is used for treatment of coagulation and 
thrombotic disorders and other medical applications [58]; 
additionally, chondroitin sulfate (CS) is a GAG used for 
osteoarthritis treatment. Their traditional association of 
animal tissues is undesirable. The analogous scenario to 
HA prompts researchers to exploit metabolic engineering 
as enabling technology for the production of these com-
plex polysaccharides in non-pathogenic microbes. Could 
the success of HA be emulated for heparin, CS, and other 
GAGs? Unlike HA, however, heparin and chondroitin are 
sulfated GAGs, with additional epimerization along the 
chain of polymer. Thus the polymer is more complex in 
chemical composition, compared to HA which is a simple 
repeats of a disaccharide. E. coli K4 and K5 strains pro-
duce non-sulfurated polymer backbones that can serve as 
CS and heparin precursors, respectively. But they lack the 
sulfotransferases and empimerase needed for the authen-
tic structures. In general, functional expression of human 
enzymes is challenging in E. coli. Thus, the approach 
worked well so far was a combination of E. coli fermen-
tation for precursor production and chemoenzymatic 
modification in  vitro for the final products [58]. Meta-
bolic engineering strategies were used to increase the titer 
of the precursor molecules. Overexpression of the tran-
scriptional regulator SlyA was effective to raise the titer to 
2.6 g/L [59] of K4, a fructosylated chondroitin. Expression 
of biosynthesis genes of K5 and K4 in laboratory strains is 
also successful. Optimization of gene expression profiles 
led to 1.88 g/L haparosan from E. coli BL21 strain [60] and 
2.4  g/L K4 polysaccharide [61]. To open up opportunity 
for in  vivo modification of the precursor K5, Barreteau 
and coworkers [62] introduced the K5 synthesis genes to 
an E. coli K12 strain for intracellular production and addi-
tionally shown that intracellularly expressed heterologous 
polysaccharide lyase degraded the polysaccharides into 
oligosaccharides. Presumably, other modifying enzymes 
can be introduced and polysaccharides can be modified 
accordingly. To potentially produce heparin in a one fer-
mentation step, an attempt was also made to engineer 
CHO cells, which proves to be challenging as while active 
expression of human N-deacetylase/N-sulforaansfrase 
was evident, the increased N-sulfo groups were not con-
sistent with pharmacological heparin [63].
Metabolic engineering can also be used for produce 
non-natural polysaccharides. Yadav and coworkers engi-
neered Gluconacetobacter xylinus, the bacterial cellu-
lose producer, to produce a mixed polysaccharide with 
glucose and GlcNAc as monomers [64]. The copolymer 
is more readily biodegradable than cellulose. The suc-
cess of this approach relies on the promiscuous nature of 
the cellulose synthase. In the future, protein engineering 
can be used, in combination of metabolic engineering, 
to tailor properties of a polysaccharide for a particular 
application. For example, fucosylated chondroitin sul-
fate from sea cucumber was recently shown in an animal 
model to activate insulin signaling [65]. If K4 polymerase 
is promiscuous enough or an engineered version could 
be found to incorporate fucose into K4, it is conceivable 
that a new type of polymer, fucosylated K4, could be pro-
duced from E. coli.
While above examples are skewed toward medically 
important polysaccharides, this certainly does not reflect 
the diverse polysaccharides produced by various organ-
isms and their potential applications. Polysaccharides 
are also produced naturally by soil microbes in vital 
processes such as symbiosis. One such polysaccharide 
is succinoglycan produced by Sinorhizobium meliloti. A 
recent work demonstrated that enhanced production of 
succinoglycan by overexpression exoY gene promoted the 
symbiosis with the host plant Medicago truncatula [66]. 
This is metabolic engineering in a non-traditional sense, 
as the product of metabolic engineering is not isolated 
from a bioreactor; rather the product is used in situ in a 
process. In the future, this may also become an important 
use of metabolic engineering. Scleroglucan is another 
example of polysaccharides useful outside medical field. 
Its non-medical application ranges from oil recovery, 
food processing, and cosmetics. The recently sequenced 
genome of Sclerotium rolfsii, opens up metabolic engi-
neering opportunities to produce the fascinating mol-
ecule in non-pathogenic microbes [67].
Glycoproteins
Biopharmaceutical industry has grown to be an industry 
with hundreds of products and market value over $100 
billion [68, 69]. About 70 % of the human protein thera-
peutics are glycoproteins [70]. Not surprisingly, since 
glycoforms are crucial for the functionality of the protein 
and therapeutic outcomes, mammalian cell lines, most 
prominently CHO, are used for glycoproteins destined 
for human use. Even with CHO cells, however, the glyco-
sylation patterns are not human enough. One difference 
between human and CHO protein is the linkage of sialic 
acid. Human sialylated proteins have both α2,6 and α2,3 
linkages, whereas CHO only produces α2,3-linked pro-
teins. This can be addressed, as Bailey described in a 1991 
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review, by metabolically engineering, specifically intro-
ducing α2,6-sialyltransferase into CHO [71]. Two recent 
reports indicate this strategy is successful in increas-
ing sialylation of commercially important glycoproteins, 
immunoglobulin (IgG) [72] and erythropoietin (EPO) 
[73]. In the case of IgG, introducing α2,6-sialyltransferase 
is sufficient to generate protein with this new linkages, 
increasing the total sialic acid content of the recombinant 
proteins up to two fold [72]. In the case of EPO, the goal 
was to increase sialylation of highly branched glycans, 
since they are more important for therapeutic functions. 
Thus, besides expression of α2,6-sialyltransferase, two 
additional glycosyltransferases were introduced to CHO 
cells, successfully increasing the tri- and tetra-sialylated 
structures. As a result, these structures account for 90 % 
of the total sialic acid of EPO produced by metabolically 
engineered CHO [73].
Besides increasing sialylation and making human-like 
glycoforms, metabolic engineering could be used to sim-
plify or install new glycoforms on a recombinant pro-
tein. For example, glycoforms can be simplified to assist 
structure studies and enhance homogeneity. Sealover 
and coworkers used zinc-finger nuclease (ZFN) genome 
editing tools to knockout the gene encoding an essential 
branching enzyme, the mannosyl (α1,3)-glycoprotein-
β1,2-acetylglcosaminyltransferase (MGAT1), creating 
neoglycoproteins with Man5GlcNAc2 structures, useful 
for x-ray crystallography studies and for vaccines target-
ing mannose receptors [74]. To install a single trisaccha-
ride glycan on recombinant protein, the Man5GlcNAc2 
structure was further trimmed down to a single GlcNAc 
by expressing a fungal endo-β-N-acetylglucosaminidase 
targeted to Golgi. The single sugar glycan (GlcNAc) was 
subsequently extended to a trisaccharide by addition of a 
galactose and a sialic acid by coexpression of two respec-
tive glycosyltransferases [75]. This metabolic engineer-
ing approach has the advantage to drastically reduce the 
complexity of glycan structures on a glycoprotein thereby 
improving glycan homogeneity. The Zinc Finger nuclease 
gene editing technique was also used to modify O-gly-
cosylation of human cell lines by knocking out chaper-
ones in the folding of key glycosyltransferases, resulting 
truncated glycans, which were enriched by affinity chro-
matography for further analysis [76]. Newer and more 
powerful genome editing techniques such as CRISPR/
Cas9 system is expected to make editing of mammalian 
cell lines easier and less prone to artifacts.
Among all alternatives to mammalian cell culture, the 
methylotrophic yeast Pichia pastoris based technology 
seems to be most advanced. Both N- and O-glycoproteins 
resembling human glycoforms could be produced from P. 
pastoris [77]. Recent research significantly improved site 
occupancy to almost 100 % [78, 79]. Process development 
and optimization, and scale up studies have been carried 
out up to several thousand liters. Product titers reached 
a g per liter level and importantly, the engineered yeast 
strain appeared to be robust, and glycosylation patterns 
are consistent across several orders of magnitude change 
in cultivation volumes [80]. A comparison in glycosyla-
tion of EPO produced by Pichia and CHO showed that 
EPO produced by Pichia is more homogenous with bi-
antennary whereas CHO produced EPO contained addi-
tional tri- and tetra-antennary structures [81], known to 
be more active for its therapeutic function, suggesting 
that the state of art yeast glycoprotein technology leaves 
room for improvement and for alternative technologies. 
Indeed, efforts in engineering plant and insect cells offer 
increasingly realistic prospect of using these potentially 
more cost-effective hosts for glycoprotein production. 
Researchers recently achieved a significant metabolic 
engineering milestone in plant, making plant cells per-
form mammalian-like glycosylation of human EPO with 
tri- and tetra-sialylation. This is significant as this is the 
only system other than CHO, capable of this type of gly-
cosylation [82]. A major goal in engineering insect cells 
is to elongate the insect glycan to human glycans which 
typically have penultimate galactose and terminal sialic 
acid. Recent efforts focused on making cells to perform 
human like glycosylation by engineering glycosyltrans-
ferase targeting [83] and inducible coordinated expres-
sion of glycosylation [84], and reduce immunogenic 
fucosylation [85].
Ever since the first functional transfer of bacterial 
N-glycosylation in Campylobacter jejuni into E. coli [86], 
the prospect of making glycoproteins in E. coli has gen-
erated much excitement. The progress over the last dec-
ades indeed has made the bacterial glycosylation much 
closer to be exploited as a realistic technology [70, 87]. 
Two areas of applications are particularly promising. The 
first is to produce glycoprotein vaccine with carbohy-
drate antigen presented on the surface of a protein car-
rier. A recent paper on the production of a recombinant 
vaccine against Burkhoderia pseudomallei illustrates how 
a protein bearing specific polysaccharide antigen can be 
synthesized in E. coli [88]. The polysaccharide antigen 
in question requires 15 genes, which was introduced in 
E. coli via a plasmid. E. coli strain was also modified by 
deletion of waaL and wecA, encoding enzymes that either 
prevent or interfere with the glycan ligation to AcrA, a 
Campylobacter glycoprotein. The ligation is catalyzed by 
PglB, the Campylobacter jejuni oligosaccaryltransferase 
[88]. Similar approach was used to develop multivalence 
vaccine when the carrier protein was an antigen itself 
and was conjugated with one or more antigenic glycans. 
Wacker and coworkers demonstrated a trivalent vaccine 
against Staphylococcus aureus [89]. Besides bacterial 
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antigens, other glycan such as human Lewis antigen asso-
ciated with autoimmune diseases could be presented 
on a protein using bacterial glycosylation systems [90], 
thanks to the relaxed glycan substrate specificity of PglB. 
Although the first glycoprotein bearing Lewis antigen 
used a combination of in vivo and in vitro methods due 
to lack of GDP-fucose biosynthesis capability of E. coli 
native strains, this deficiency can be addressed using 
metabolic engineering strategies. Thus we could expect 
that in the future a designer glycoprotein vaccine carry-
ing one or more antigens from diverse biological sources 
could be made by metabolically engineered E. coli cells in 
a one fermentation step.
Recombinant bacterial glycosylation systems can also 
be exploited for production of glycoprotein therapeutics 
currently on market, or hundreds of others in various 
stages of development. While the mechanism and meth-
odology are the same as those used for vaccine develop-
ment, the current research in this applications focuses 
on increasing glycoprotein titers, glycosylation efficiency 
(occupancy), and authenticity of glycans, as most of these 
therapeutic proteins are for human uses [91–93]. The 
bacterial system, while having the potential to revolution-
ize the manufacture technology, currently is not com-
petitive with the mammalian technology, nor with any of 
the alternatives (Pichia, plant, and insect cells) reviewed 
above. The titer of glycoproteins from E. coli cells is in 
mg/L range, 2–3 orders of magnitude lower than those 
of other technologies. Glycan structures on glycoproteins 
derived from bacterial systems are still quite a distance 
from those of human or even mammalian like. For exam-
ple, no sialylated glycoproteins has made from bacte-
rial system. Glycosylation efficiency is also mostly lower 
than <50 %, sometime 1 %, far lower than desired com-
plete glycosylation [94]. However, these challenges are 
not insurmountable, especially considering the relatively 
short period of time the progress has made. Recent suc-
cesses in expressing human sialyltranferase (ST6) [95] 
and human glycosyltransferase GalNAc T2 [96] in E. coli 
bring it closer to a bacterial technology capable of pro-
ducing humanized glycoproteins.
Conclusions
Glycosidic bond formation catalyzed by glycosyltrans-
ferase enzymes is in the center of the synthesis of most 
glycan structures in nature. Oligosaccharides, polysac-
charides, and glycoproteins share the commonality that 
requires glycosyltransferases in their synthesis, differing 
only in the nature of the acceptors. Not reviewed above, 
glycolipids are similarly synthesized with a lipid as an 
acceptor. Glycosylated natural products, predominantly 
represented by some antibiotics such as vancomycin, 
also requires glycosyltransferase enzyme in the synthesis. 
Therefore, from a metabolic engineering point of view, 
they share much of the synthesis challenges. These 
include, as analyzed above, the high energy demand due 
to the need for sugar nucleotides as precursors, the com-
plexity of metabolic pathways and regulations involved, 
and the adequate supply of acceptors when and where 
the glycosyltransferases are most active. Represented by 
2′-fucosyllactose, HA, and EPO, the success in bringing 
highly valuable oligo- and poly-saccharides, and glyco-
proteins to commercial production demonstrates the 
power of this branch of metabolic engineering. On the 
other hand, given the enormous diversity and significant 
complexity of saccharide-containing structures, a hand-
ful of molecules attaining commercial success can only 
qualify as a promising beginning. In fact, the surface of 
the gigantic glyco-sphere has barely scratched. Provid-
ing scientists with hundreds and thousands of glycans in 
quantities sufficient to probe their structure and function 
relationships and supplying clinicians with selective com-
pounds (such as Globo H and heparin in kg quantities) 
for clinical studies in a cost effective manner are chal-
lenges before metabolic engineers and synthetic biolo-
gists. The inherent challenges in complex carbohydrates 
demand innovative metabolic engineering strategies 
beyond a simple extension of those used in successful 
examples reviewed here. Thus, this branch of metabolic 
engineering will sure grow and the rewards in this inter-
disciplinary field are sweet and plentiful.
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